The efficacy of pentoxifylline for major depressive disorder : A systematic review and meta-analysis of randomized controlled trials - PubMed
a day ago
- #depression
- #pentoxifylline
- #meta-analysis
- Pentoxifylline shows promise as an adjunctive therapy for major depressive disorder (MDD).
- A meta-analysis of 4 randomized controlled trials (RCTs) with 292 participants found significant improvements in response and remission rates with pentoxifylline.
- The pooled odds ratio (OR) for treatment response was 6.85 (95% CI: 3.42, 13.73), indicating a much higher likelihood of response compared to control groups.
- Remission rates also favored pentoxifylline, with a pooled OR of 6.09 (95% CI: 3.11, 11.91).
- Further research is needed to confirm efficacy across diverse patient populations.